JY
HQL

Jeff Yass’s abrdn Life Sciences Investors HQL Stock Holding History

Jeff Yass’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-29,393
Closed -$650K – 9805
2014
Q3 		$650K Sell
29,393
-197,326
-87% -$4.29M ﹤0.01% 6725
2014
Q2 		$4.71M Buy
+226,719
New +$4.76M ﹤0.01% 3185

Other funds holding HQL

NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $15.9B AUM 53.4% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

Jeff Yass's HQL Position: Q4 2014 in Review

Jeff Yass sold out of abrdn Life Sciences Investors (HQL) in Q4 2014, closing a stake of 29,393 shares — an estimated $650K sold.

Jeff Yass first reported a position in HQL in Q2 2014 and held it in 2 quarters. The position peaked at $4.71M in Q2 2014. 45 funds tracked by Wall St. Rank hold HQL as of Q4 2014.

  • Jeff Yass reported no remaining abrdn Life Sciences Investors position as of Q4 2014 after selling out during the quarter.
  • Jeff Yass sold 29,393 abrdn Life Sciences Investors shares in Q4 2014, an estimated $650K.
  • Jeff Yass first reported a position in abrdn Life Sciences Investors in Q2 2014 and held it in 2 quarters.
  • Jeff Yass's abrdn Life Sciences Investors position peaked at $4.71M in Q2 2014.
  • 45 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2014.

Based on Susquehanna International Group's 13F filing for Q4 2014, filed 17 Feb 2015.